The primary biliary cholangitis (PBC) treatment market — therapies for a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small and medium-sized intrahepatic bile ducts — has experienced one of the most consequential shakeups in its treatment history within just the past year, with the Primary Biliary Cholangitis Treatment Market reflected...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek